271 related articles for article (PubMed ID: 26847364)
21. Moving beyond rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone for diffuse large B-cell lymphoma.
Roschewski M; Dunleavy K; Wilson WH
Leuk Lymphoma; 2014 Nov; 55(11):2428-37. PubMed ID: 24438195
[TBL] [Abstract][Full Text] [Related]
22. BCL2 positive and BCL6 negative diffuse large B cell lymphoma patients benefit from R-CHOP therapy irrespective of germinal and non germinal center B cell like subtypes.
Jovanovic MP; Mihaljevic B; Jakovic L; Martinovic VC; Fekete MD; Andjelic B; Antic D; Bogdanovic A; Boricic N; Terzic T; Jelicic J; Milenkovic S
J BUON; 2015; 20(3):820-8. PubMed ID: 26214636
[TBL] [Abstract][Full Text] [Related]
23. Diffuse aggressive lymphoma.
Fisher RI; Miller TP; O'Connor OA
Hematology Am Soc Hematol Educ Program; 2004; ():221-36. PubMed ID: 15561685
[TBL] [Abstract][Full Text] [Related]
24. High Ki-67 expression in diffuse large B-cell lymphoma patients with non-germinal center subtype indicates limited survival benefit from R-CHOP therapy.
Li ZM; Huang JJ; Xia Y; Zhu YJ; Zhao W; Wei WX; Jiang WQ; Lin TY; Huang HQ; Guan ZZ
Eur J Haematol; 2012 Jun; 88(6):510-7. PubMed ID: 22413767
[TBL] [Abstract][Full Text] [Related]
25. Activity and safety of dose-adjusted infusional cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy with rituximab in very elderly patients with poor-prognostic untreated diffuse large B-cell non-Hodgkin lymphoma.
Musolino A; Boggiani D; Panebianco M; Vasini G; Salvagni S; Franciosi V; Ardizzoni A
Cancer; 2011 Mar; 117(5):964-73. PubMed ID: 20960528
[TBL] [Abstract][Full Text] [Related]
26. CD30 expression in de novo diffuse large B-cell lymphoma: a population-based study from British Columbia.
Slack GW; Steidl C; Sehn LH; Gascoyne RD
Br J Haematol; 2014 Dec; 167(5):608-17. PubMed ID: 25135752
[TBL] [Abstract][Full Text] [Related]
27. Improving outcomes for patients with diffuse large B-cell lymphoma.
Flowers CR; Sinha R; Vose JM
CA Cancer J Clin; 2010; 60(6):393-408. PubMed ID: 21030533
[TBL] [Abstract][Full Text] [Related]
28. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia.
Sehn LH; Donaldson J; Chhanabhai M; Fitzgerald C; Gill K; Klasa R; MacPherson N; O'Reilly S; Spinelli JJ; Sutherland J; Wilson KS; Gascoyne RD; Connors JM
J Clin Oncol; 2005 Aug; 23(22):5027-33. PubMed ID: 15955905
[TBL] [Abstract][Full Text] [Related]
29. Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles.
Cunningham D; Hawkes EA; Jack A; Qian W; Smith P; Mouncey P; Pocock C; Ardeshna KM; Radford JA; McMillan A; Davies J; Turner D; Kruger A; Johnson P; Gambell J; Linch D
Lancet; 2013 May; 381(9880):1817-26. PubMed ID: 23615461
[TBL] [Abstract][Full Text] [Related]
30. Everolimus combined with R-CHOP-21 for new, untreated, diffuse large B-cell lymphoma (NCCTG 1085 [Alliance]): safety and efficacy results of a phase 1 and feasibility trial.
Johnston PB; LaPlant B; McPhail E; Habermann TM; Inwards DJ; Micallef IN; Colgan JP; Nowakowski GS; Ansell SM; Witzig TE
Lancet Haematol; 2016 Jul; 3(7):e309-16. PubMed ID: 27374464
[TBL] [Abstract][Full Text] [Related]
31. A phase II trial of RCHOP followed by radioimmunotherapy for early stage (stages I/II) diffuse large B-cell non-Hodgkin lymphoma: ECOG3402.
Witzig TE; Hong F; Micallef IN; Gascoyne RD; Dogan A; Wagner H; Kahl BS; Advani RH; Horning SJ
Br J Haematol; 2015 Sep; 170(5):679-86. PubMed ID: 25974212
[TBL] [Abstract][Full Text] [Related]
32. Prognostic impact of p53 aberrations for R-CHOP-treated patients with diffuse large B-cell lymphoma.
Stefancikova L; Moulis M; Fabian P; Vasova I; Zedek F; Ravcukova B; Muzik J; Kuglik P; Vranova V; Falkova I; Hrabalkova R; Smardova J
Int J Oncol; 2011 Dec; 39(6):1413-20. PubMed ID: 21874232
[TBL] [Abstract][Full Text] [Related]
33. CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group.
Pfreundschuh M; Kuhnt E; Trümper L; Osterborg A; Trneny M; Shepherd L; Gill DS; Walewski J; Pettengell R; Jaeger U; Zinzani PL; Shpilberg O; Kvaloy S; de Nully Brown P; Stahel R; Milpied N; López-Guillermo A; Poeschel V; Grass S; Loeffler M; Murawski N;
Lancet Oncol; 2011 Oct; 12(11):1013-22. PubMed ID: 21940214
[TBL] [Abstract][Full Text] [Related]
34. A phase II study of ibrutinib in combination with rituximab-cyclophosphamide-doxorubicin hydrochloride-vincristine sulfate-prednisone therapy in Epstein-Barr virus-positive, diffuse large B cell lymphoma (54179060LYM2003: IVORY study): results of the final analysis.
Yoon SE; Kim SJ; Yoon DH; Koh Y; Mun YC; Do YR; Choi YS; Yang DH; Kim MK; Lee GW; Suh C; Ko YH; Kim WS
Ann Hematol; 2020 Jun; 99(6):1283-1291. PubMed ID: 32333154
[TBL] [Abstract][Full Text] [Related]
35. Matched-pair analysis comparing the outcomes of T cell/histiocyte-rich large B cell lymphoma and diffuse large B cell lymphoma in patients treated with rituximab-CHOP.
Kim YS; Ji JH; Ko YH; Kim SJ; Kim WS
Acta Haematol; 2014; 131(3):156-61. PubMed ID: 24192382
[TBL] [Abstract][Full Text] [Related]
36. Strikingly high false positivity of surveillance FDG-PET/CT scanning among patients with diffuse large cell lymphoma in the rituximab era.
Avivi I; Zilberlicht A; Dann EJ; Leiba R; Faibish T; Rowe JM; Bar-Shalom R
Am J Hematol; 2013 May; 88(5):400-5. PubMed ID: 23423884
[TBL] [Abstract][Full Text] [Related]
37. Interim fluorine-18 fluorodeoxyglucose PET-computed tomography and cell of origin by immunohistochemistry predicts progression-free and overall survival in diffuse large B-cell lymphoma patients in the rituximab era.
de Oliveira Costa R; Hallack Neto A; Siqueira S; Lage LA; de Paula HM; Coutinho AM; Pereira J
Nucl Med Commun; 2016 Oct; 37(10):1095-101. PubMed ID: 27281359
[TBL] [Abstract][Full Text] [Related]
38. Importance of maintaining the relative dose intensity of CHOP-like regimens combined with rituximab in patients with diffuse large B-cell lymphoma.
Hirakawa T; Yamaguchi H; Yokose N; Gomi S; Inokuchi K; Dan K
Ann Hematol; 2010 Sep; 89(9):897-904. PubMed ID: 20414658
[TBL] [Abstract][Full Text] [Related]
39. Frontline treatment of diffuse large B-cell lymphoma: Beyond R-CHOP.
Mondello P; Mian M
Hematol Oncol; 2019 Oct; 37(4):333-344. PubMed ID: 30938848
[TBL] [Abstract][Full Text] [Related]
40. Prognostic significance of maximum tumour (bulk) diameter in young patients with good-prognosis diffuse large-B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: an exploratory analysis of the MabThera International Trial Group (MInT) study.
Pfreundschuh M; Ho AD; Cavallin-Stahl E; Wolf M; Pettengell R; Vasova I; Belch A; Walewski J; Zinzani PL; Mingrone W; Kvaloy S; Shpilberg O; Jaeger U; Hansen M; Corrado C; Scheliga A; Loeffler M; Kuhnt E;
Lancet Oncol; 2008 May; 9(5):435-44. PubMed ID: 18400558
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]